Cellipont Bioservices, a Texas-based cell therapy contract development and manufacturing organization, has supported six client projects that are expected to reach Investigational New Drug (IND) application submission in 2026.

The company’s support spans process development, analytical development, current Good Manufacturing Practices (cGMP) manufacturing, quality, testing, and program management. Depending on program requirements, activities can include process optimization, analytical method development, technology transfer, raw material planning, cGMP manufacturing, quality control testing, stability support, as well as preparation of manufacturing and analytical information for regulatory submissions.

Cellipont’s purpose-built Texas facility supports autologous and allogeneic cell therapy programs from early development through clinical manufacturing. The company said its teams coordinate scientific, technical, operational, and quality activities for each client program based on its manufacturing and development requirements.

The six programs add to Cellipont’s manufacturing activity since the facility began GMP operations in June 2025. In July 2026, the company reported releasing its 100th GMP batch approximately one year after starting GMP manufacturing. Cellipont said the milestone included production across multiple client programs and involved teams in manufacturing, quality, supply chain, manufacturing science and technology, facilities, and validation.